Cantor Fitzgerald Has Negative View of BCRX FY2025 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for shares of BioCryst Pharmaceuticals in a report issued on Monday, June 30th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the biotechnology company will earn $0.06 per share for the year, down from their previous estimate of $0.09. Cantor Fitzgerald has a "Overweight" rating and a $20.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. Cantor Fitzgerald also issued estimates for BioCryst Pharmaceuticals' FY2026 earnings at $0.27 EPS.

Several other analysts also recently issued reports on BCRX. Bank of America lifted their target price on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Tuesday. Wedbush lifted their price objective on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a research report on Monday. Royal Bank Of Canada restated an "outperform" rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday. Barclays lifted their price target on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. Finally, Needham & Company LLC reissued a "buy" rating and set a $17.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, June 25th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $16.70.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock traded down $0.08 during trading hours on Tuesday, hitting $8.95. The company's stock had a trading volume of 1,407,127 shares, compared to its average volume of 3,032,538. The company has a market cap of $1.87 billion, a PE ratio of -34.40, a PEG ratio of 2.55 and a beta of 1.04. The business has a 50 day moving average price of $10.06 and a two-hundred day moving average price of $8.60. BioCryst Pharmaceuticals has a 12-month low of $6.02 and a 12-month high of $11.31.

Institutional Trading of BioCryst Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Doliver Advisors LP grew its position in BioCryst Pharmaceuticals by 269.1% in the second quarter. Doliver Advisors LP now owns 274,328 shares of the biotechnology company's stock worth $2,458,000 after acquiring an additional 200,000 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of BioCryst Pharmaceuticals by 3.9% in the 1st quarter. Rhumbline Advisers now owns 321,154 shares of the biotechnology company's stock valued at $2,409,000 after purchasing an additional 12,022 shares during the last quarter. Strs Ohio purchased a new position in shares of BioCryst Pharmaceuticals in the 1st quarter worth approximately $284,000. Acadian Asset Management LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 244.1% in the 1st quarter. Acadian Asset Management LLC now owns 670,361 shares of the biotechnology company's stock worth $5,023,000 after purchasing an additional 475,564 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of BioCryst Pharmaceuticals by 11.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company's stock valued at $3,363,000 after purchasing an additional 47,355 shares during the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.